Altimmune (ALT) Common Equity (2016 - 2025)
Historic Common Equity for Altimmune (ALT) over the last 17 years, with Q3 2025 value amounting to $185.6 million.
- Altimmune's Common Equity rose 3915.52% to $185.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $185.6 million, marking a year-over-year increase of 3915.52%. This contributed to the annual value of $123.5 million for FY2024, which is 3636.86% down from last year.
- Per Altimmune's latest filing, its Common Equity stood at $185.6 million for Q3 2025, which was up 3915.52% from $161.4 million recorded in Q2 2025.
- Altimmune's Common Equity's 5-year high stood at $246.4 million during Q1 2021, with a 5-year trough of $123.5 million in Q4 2024.
- Over the past 5 years, Altimmune's median Common Equity value was $184.9 million (recorded in 2022), while the average stood at $179.9 million.
- Its Common Equity has fluctuated over the past 5 years, first surged by 48820.26% in 2021, then plummeted by 3636.86% in 2024.
- Over the past 5 years, Altimmune's Common Equity (Quarter) stood at $199.1 million in 2021, then decreased by 6.95% to $185.3 million in 2022, then grew by 4.75% to $194.1 million in 2023, then crashed by 36.37% to $123.5 million in 2024, then soared by 50.27% to $185.6 million in 2025.
- Its Common Equity stands at $185.6 million for Q3 2025, versus $161.4 million for Q2 2025 and $142.2 million for Q1 2025.